Division of Ophthalmology, Department of Special Surgery, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Biomolecules. 2023 Nov 8;13(11):1630. doi: 10.3390/biom13111630.
: The global epidemic status of diabetic retinopathy (DR) and its burden presents an ongoing challenge to health-care systems. It is of great interest to investigate potential prognostic biomarkers of DR. Such markers could aid in detecting early stages of DR, predicting DR progression and its response to therapeutics. Herein, we investigate the prognostic value of intravitreal concentrations of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) in a DR cohort. : Vitreous sample acquisition was conducted at King Abdullah University Hospital (KAUH) between December 2020 and June 2022. Samples were obtained from any patient scheduled to undergo a pars plana vitrectomy (PPV) for any indication. Included patients were categorized into a DR group or a corresponding non-diabetic (ND) control group. Demographics, clinicopathological variables, standardized laboratory tests results, and optical coherence tomography (OCT) data were obtained for each included individual. Intravitreal concentrations of VEGF and PDGF were assessed using commercial enzyme-linked immunosorbent assay (ELISA). : A total of 80 eyes from 80 patients (DR group: = 42 and ND control group: = 38) were included in the analysis. The vitreous VEGF levels were significantly higher in the DR group compared to the ND control group (DR group 5744.06 ± 761.5 pg/mL versus ND control group 817.94 ± 403.1 pg/mL, = 0.0001). In addition, the vitreous PDGF levels were also significantly higher in the DR group than those in the ND control group (DR group 4031.51 ± 410.2 pg/mL versus ND control group 2691.46 ± 821.0 pg/mL, = 0.001). Bassline differences between test groups and clinical factors impacting VEGF and PDGF concentrations were investigated as well. Multiple regression analysis indicated PDGF as the sole independent risk factor affecting best-corrected visual acuity (BCVA) at the last follow-up visit: the higher the PDGF vitreous levels, the worst the BCVA. : Vitreous concentrations of VEGF and PDGF are correlated with DR severity and may exhibit a possible prognostic potential value in DR. Further clinical and experimental data are warranted to confirm the observed findings and to help incorporate them into daily practice.
: 糖尿病视网膜病变(DR)的全球流行状况及其负担对医疗保健系统构成了持续挑战。研究 DR 的潜在预后生物标志物具有重要意义。这些标志物可以帮助检测 DR 的早期阶段,预测 DR 的进展及其对治疗的反应。在此,我们研究了 DR 队列中玻璃体内血管内皮生长因子(VEGF)和血小板衍生生长因子(PDGF)浓度的预后价值。: 玻璃体液样本采集于 2020 年 12 月至 2022 年 6 月在阿卜杜拉国王大学医院(KAUH)进行。样本取自任何因任何原因计划接受标准平面玻璃体切除术(PPV)的患者。纳入的患者分为 DR 组或相应的非糖尿病(ND)对照组。对每位纳入个体进行了人口统计学、临床病理变量、标准化实验室检测结果和光学相干断层扫描(OCT)数据的获取。使用商业酶联免疫吸附试验(ELISA)评估玻璃体内 VEGF 和 PDGF 的浓度。: 共有 80 只眼(80 例患者)纳入分析,其中 DR 组 42 只眼,ND 对照组 38 只眼。DR 组玻璃体内 VEGF 水平明显高于 ND 对照组(DR 组 5744.06 ± 761.5 pg/mL 与 ND 对照组 817.94 ± 403.1 pg/mL, = 0.0001)。此外,DR 组玻璃体内 PDGF 水平也明显高于 ND 对照组(DR 组 4031.51 ± 410.2 pg/mL 与 ND 对照组 2691.46 ± 821.0 pg/mL, = 0.001)。还研究了实验组之间的基线差异以及影响 VEGF 和 PDGF 浓度的临床因素。多元回归分析表明 PDGF 是影响最后一次随访最佳矫正视力(BCVA)的唯一独立危险因素:玻璃体内 PDGF 水平越高,BCVA 越差。: 玻璃体内 VEGF 和 PDGF 浓度与 DR 严重程度相关,在 DR 中可能具有潜在的预后价值。需要进一步的临床和实验数据来证实观察到的结果,并帮助将其纳入日常实践。